EVALUATION OF CD9 & CD56 ANTIGENS EXPRESSION IN ADULT ACUTE MYELOID LEUKAEMIA.

Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Background: -Acute myeloid leukaemia (AML) is a malignant clonal disorder resulting from the neoplastic proliferation of a clone of myeloid cells. Flow cytometry is used for confirming diagnosis, identifying prognostic differences, staging of AML and detecting an aberrant immunophenotype that can be used for monitoring of complete remission (CR) achievement. Objectives: - To evaluate the expression of aberrant CD9 and CD56 in newly diagnosed adult AML patients and their association with clinical and haematological parameters and with CR achievement. Methods: -Thirty adult patients (>15 years) who were newly diagnosed de novo AML were selected from the Baghdad Teaching Hospital andAl- ImameinKadhimein medical cityfrom July 2015 to March 2016. All patients were grouped according to FAB classification and evaluated individually and the diagnosis was based on the morphology, cytochemistry or flow cytometry. Aberrant antigens CD9 and CD56 expressions were investigated by four- colours flow cytometry at the time of diagnosis. The patients were evaluated at day 28 from the start of chemotherapy to assess complete remission achievement. Verbal consent was taken from the patients. Results: -The aberrant expression of CD56, CD9 were observed in 23.3% and 33.3% of AML patients respectively. CD56 was expressed more with monocytic differentiation and CD9 was expressed more with M2 cases. CD56 expression was significantly associated with high total WBC count, high peripheral blood and bone marrow blast cells and the extramedullary manifestations. There was significant association between CD56 and CD9 expression regardless of their intensity of the markers with non-responsiveness to induction therapy. Conclusion: -Aberrant CD9 and CD56 antigens were associated with adverse clinical and hematological parameters at presentation as well as with low cure rate.

  1. Shipley JL and Butera JN. Acute myelogenous leukemia. ExpHematol2009;37:649?58.
  2. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology andetiology. Cancer 2006; 107(9): 2099-2107.3.
  3. Akagi T, Ogawa S, Dugas M, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica 2009; 94(2): 213-223.
  4. Bain BJ. Classification of acute leukaemia: the need to incorporate cytogenetic and molecular genetic information. J ClinPathol 1998; 51: 420- 423.
  5. Behm FG. Classification of acute leukemias. Available at:www.springer.com/cda/.../9780896038349-c2.pdf (accessed on 4 Oct 2015).
  6. Zuckerman T, Rowe JM. Acute leukaemia. In: Schmaier AH, LazarusHM,editors. Concise Guide to Hematology. First edition: Wiley Balckwell;2012; 19: 235-250.
  7. D?hner H, Estey EH, Amadori S et al. Diagnosis and management of acutemyeloid leukemia in adults: recommendations from an international expertpanel, on behalf of the European Leukemia Net. Blood 2010; 115(3): 453-474.
  8. Bain BJ, Swirsky D. Erythrocyte and leucocyte cytochemistry. In: Bain BJ,Bates I, Laffan MA et al. editors. Dacie and Lewis practical hematology. 11th Philadelphia: Churchill Livingstone Elsevier 2011; 15: 333-352.
  9. Naeim F, Rao PN. Acute myeloid leukemia. In: Naeim F, Rao PN, GrodyWW, editors. Haematopathology: morphology, immunophenotype, cytogenetic,and molecular approaches. Oxford: Elsevier Inc 2008; 11: 207-251.
  10. Orfao A, Ortuno F, Santiago M, et al. Immunophenotyping of acuteleukemias and myelodysplastic syndromes. Cytometry Part A 2004; 58A: 62-71.
  11. Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000;96(3): 870-877.
  12. Immunophenotyping and cytogenetic/molecular genetic analysis in leukemiaand related conditions. Barbara J. Bain, Leukemia diagnosis. Fourth edition.Hong Kong. Wiley-Blackwell 2010; 64-107.
  13. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, andfusion events and define a novel type of membrane microdomain. Annu Rev CellDevBiol 2003; 19:397-422.
  14. Reyes AA, Small SJ, Akeson R. "At least 27 alternatively spliced forms ofthe neural cell adhesion molecule mRNA are expressed during heartdevelopment". Molecular and Cellular Biology 2011; (3): 1654?1661.
  15. CyFlow? Cube 6. Available at:
  16. http://www.sysmexpartec.com/instrumentation/products.html?&tx_cyclosproductfinder_cyc_pf_dis
  17. play[product]=1024&tx_cyclosproductfinder_cyc_pf_display[action]=show&tx_cyclosproductfinder_cyc_pf_display[controller]=Product (accessed 20 Feb2016).
  18. Berditchevski F. Complexes of tetraspanins with integrins: More than meetsthe eye. J Cell Sci 2001; 114:4143-4151.
  19. Dhahir EK. The Significance of FLT3-ITD Mutation and NucleophosminMutation in Acute Leukemia. A thesis Submitted to the College of Medicine ?Al Nahrain University in Partial Fulfillment of the Requirement for the Degreeof Doctor of Philosophy in Pathology (Hematology) 2012.
  20. Gari M., Abuzenadah A., Chaudhary A., et al.: Detection of FLT3 OncogeneMutations in Acute Myeloid Leukemia Using Conformation Sensitive GelElectrophoresis .Int. J. Mol. Sci 2008; 9: 2194-2204.
  21. Alwan AF, Zedan ZJ, Salman OS. Acute myeloid leukemia: clinical featuresand follow-up of 115 Iraqi patients admitted to Baghdad Teaching Hospital.Tikrit Medical Journal 2009; 15(1): 1-8.
  22. Hussein SH. Survey of Adult de novo Acute Myeloid Leukemia cases reportedin the Medical City in Baghdad through the years (2005-2011). A thesisSubmitted to the College of Medicine ?University of Baghdad in PartialFulfillment of the Requirement for the Degree of Master of Hematology 2013.
  23. Pouls RK, Shamoon RP, Muhammed NS. Clinical and haematologicalparameters in adult AML patients: a four year experience at NanakalyHospitalfor blood diseases. Zanco J Med Sci 2012; 16(3): 199-203.
  24. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigen expression in acutemyeloid leukemia identifies patients with poor prognosis. Leukemia.2001;15:1161?1164
  25. Dina J, Salaün V, Reman O, et al. Interest of immunophenotyping in acutemyeloid leukemia. Haematologica 2002; 87: 14-15.
  26. El-Sissy AH, El-Mashari MA, Bassuni WY et al. Aberrant lymphoid antigenexpression in acute myeloid leukemia in Saudi Arabia. Journal ofthe Egyptian Nat. Cancer Inst 2006; 18(3): 244-249.
  27. Olteanu H, Harrington AM, Kroft SH, et al. The incidence of CD56 expressionby flow cytometry in acute promyelocytic leukemia in patients treated with alltransretinoic acid and anthracycline drug combinations. Available at:http://pathology.mcw.edu/blog/the-incidence-of-cd56-expression/ (accessed 7
  28. August 2014).
  29. Graf M, Reif S, Hecht K , et al. High expression of costimulatory moleculescorrelates with low relapse-free survival probability in acute myeloid leukemia(AML). Ann Hematol 2005; 84(5): 287-297.
  30. Chang H, Brandwein J, Qi-Long yi, et al. Extramedullary infiltrates of AMLare associated with CD56 expression, 11q23 abnormalities and inferior clinicaloutcome. Leukemia Research 2004; 28(10): 1007-1011.

[Subh S. Al-Mudallal, Hind Shaker Al-Mamoori and AlaaShamikh Hassan (2017); EVALUATION OF CD9 & CD56 ANTIGENS EXPRESSION IN ADULT ACUTE MYELOID LEUKAEMIA. Int. J. of Adv. Res. 5 (Jan). 2138-2150] (ISSN 2320-5407). www.journalijar.com

HIND SHAKER AL-MAMOORI
AL-NAHRAIN UNIVERSITY- COLLEGE OF MEDICINE

DOI:

Article DOI: 10.21474/IJAR01/2988      
DOI URL: https://dx.doi.org/10.21474/IJAR01/2988

Download Full Paper

Download PDF No. of Downloads: 41 | No. of Views: 223